Metabolic Modulation of Epigenetics in Gliomas

Brain Pathology

Volumn 23, Issue 2, 2013, Pages 217-221

  Venneti, Sriram ^a   Thompson, Craig B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

epigenetics; glioma; IDH1; metabolism; PKM2.

Indexed keywords

2 HYDROXYGLUTARIC ACID; CYCLIN D1; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 3; HISTONE H3; ISOCITRATE DEHYDROGENASE 1;

ASTROCYTOMA; CANCER GRADING; CONFERENCE PAPER; CPG ISLAND; DISEASE SEVERITY; EPIGENETICS; GENE MUTATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HISTONE MODIFICATION; HUMAN; NEUROMODULATION; NONHUMAN; OLIGODENDROGLIOMA;

BRAIN NEOPLASMS; CARRIER PROTEINS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GLIOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MEMBRANE PROTEINS; MUTATION; THYROID HORMONES;

EID: 84874451397     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12022     Document Type: Conference Paper

References (52)

1. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von, Deimling A, (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116: 597-602.
3. Berger SL, (2007) The complex language of chromatin regulation during transcription. Nature 447: 407-412.
4. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, et al (2009) IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat 30: 7-11.
5. Buzzai M, Bauer DE, Jones RG, Deberardinis RJ, Hatzivassiliou G, Elstrom RL, Thompson CB, (2005) The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 24: 4165-4173.
6. Capper D, Zentgraf H, Balss J, Hartmann C, von, Deimling A, (2009) Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 118: 599-601.
7. Chaneton B, Gottlieb E, (2012) Rocking cell metabolism: revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci 37: 309-316.
8. Chen J, Liu H, Liu J, Qi J, Wei B, Yang J, et al (2013) H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet 45: 34-42.
9. Chi P, Allis CD, Wang GG, (2010) Covalent histone modifications- miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10: 457-469.
10. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al (2011) The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12: 463-469.
11. Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA, Marsit CJ, et al (2011) DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 103: 143-153.
12. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230-233.
13. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al (2010) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 465: 966.
14. Dang W, Steffen KK, Perry R, Dorsey JA, Johnson FB, Shilatifard A, et al (2009) Histone H4 lysine 16 acetylation regulates cellular lifespan. Nature 459: 802-807.
15. Dubuc AM, Mack S, Unterberger A, Northcott PA, Taylor MD, (2012) The epigenetics of brain tumors. Methods Mol Biol 863: 139-153.
16. Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, et al (2012) A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res 12: 2339-2355.
17. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, et al (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64: 3892-3899.
18. Esteve PO, Chin HG, Smallwood A, Feehery GR, Gangisetty O, Karpf AR, et al (2006) Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev 20: 3089-3103.
19. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, et al (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
20. Goidts V, Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S, et al (2012) RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. Oncogene 31: 3235-3243.
21. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118: 469-474.
22. Huse JT, Holland EC, (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331.
23. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y, (2010) Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466: 1129-1133.
24. Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B, (2010) Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro Oncol 12: 1102-1112.
25. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124: 439-447.
26. Kreth S, Thon N, Kreth FW, (2012) Epigenetics in human gliomas. Cancer Lett [Epub ahead of print].
27. Laffaire J, Everhard S, Idbaih A, Criniere E, Marie Y, de, Reynies A, et al (2011) Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 13: 84-98.
28. Lin SJ, Defossez PA, Guarente L, (2000) Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 289: 2126-2128.
29. Loenarz C, Schofield CJ, (2008) Expanding chemical biology of 2-oxoglutarate oxygenases. Nat Chem Biol 4: 152-156.
30. Lohmann F, Loureiro J, Su H, Fang Q, Lei H, Lewis T, et al (2010) KMT1E mediated H3K9 methylation is required for the maintenance of embryonic stem cells by repressing trophectoderm differentiation. Stem Cells 28: 201-212.
31. Lu C, Thompson CB, (2012) Metabolic regulation of epigenetics. Cell Metab 16: 9-17.
32. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483: 474-478.
33. Martinez R, Esteller M, (2010) The DNA methylome of glioblastoma multiforme. Neurobiol Dis 39: 40-46.
34. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522.
35. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
36. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482: 226-231.
37. Shyh-Chang N, Locasale JW, Lyssiotis CA, Zheng Y, Teo RY, Ratanasirintrawoot S, et al (2013) Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science 339: 222-226.
38. Strahl BD, Allis CD, (2000) The language of covalent histone modifications. Nature 403: 41-45.
39. Strobl-Mazzulla PH, Sauka-Spengler T, Bronner-Fraser M, (2010) Histone demethylase JmjD2A regulates neural crest specification. Dev Cell 19: 460-468.
40. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22: 425-437.
41. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324: 930-935.
42. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483: 479-483.
43. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
44. Venneti S, Felicella MM, Coyne T, Phillips JJ, Gorovets D, Huse JT, et al (2012) Histone 3 lysine 9 trimethylation (H3K9me3) is differentially associated with isocitrate dehydrogenase 1 (IDH1) R132H mutations in oligodendrogliomas and high-grade astrocytomas. (2013) Journal of Neuropathology & Experimental Neurology: (In Press).
45. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234.
46. Wellen KE, Hatzivassiliou G, Sachdeva UM, Bui TV, Cross JR, Thompson CB, (2009) ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324: 1076-1080.
47. Wolf A, Agnihotri S, Munoz D, Guha A, (2011) Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol Dis 44: 84-91.
48. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44: 251-253.
49. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, et al (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 19: 17-30.
50. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
51. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al (2012) PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150: 685-696.
52. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al (2011) Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 480: 118-122.